Talazoparib plus radiation for recurrent gynecologic cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent before any study testing or procedures.
- Your cancer is confirmed by pathology and has recurred in the abdomen/pelvis (ovary, fallopian tube, primary peritoneal, endometrium, vagina, or cervix).
- You can get pelvic/abdominal radiation: at least one measurable tumor spot that has not been radiated before.
- Your blood counts and organs are strong enough (enough hemoglobin, neutrophils, and platelets, and acceptable liver/kidney tests).
- You must not have certain prior treatments or recent treatment overlap (no chemo/radiation/immunotherapy/other investigational drugs in the last 3 weeks).
- If you can become pregnant, you must use two reliable birth-control methods during the study, and you must not be breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
This Phase 1 trial tests whether the medicine talazopib, given along with chest radiation, can better control extensive-stage small-cell lung cancer after initial chemotherapy. It is for people whose cancer has not worsened after finishing standard chemotherapy.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a PARP inhibitor (olaparib) for people whose ovarian cancer came back at least 6 months after finishing platinum-based chemo. The goal is to see if this approach is safe and works better than chemo alone.
Hear when a new Malignant Female Reproductive System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.